HR+/HER2- metastatic breast cancer
Clinical trials for HR+/HER2- metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- metastatic breast cancer trials appear
Sign up with your email to follow new studies for HR+/HER2- metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Scientists hunt for genetic signs that show which breast cancer patients will benefit from kisqali
Knowledge-focused OngoingThis study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
How do breast cancer drugs work in real life? new study digs into medical records
Knowledge-focused OngoingThis study looks at how Palbociclib and other CDK4/6 inhibitors are actually used in patients with a common type of advanced breast cancer (HR+/HER2-). Researchers will analyze anonymous medical records from routine care to see how long patients stay on treatment and whether it d…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC